Keywords: Idenix, Hepatitis C program, Novartis, FDA, Clinical hold
Idenix Pharma slumps as US FDA puts “clinical hold” on two of the firm’s hepatitis C programs
Article | 08 September 2010
Shares in US drug developer Idenix Pharmaceuticals (Nasdaq: IDIX) plunged 55% in pre-marketing trading yesterday after the company said it had ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
